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SPECIFIC AIMS
Aldose reductase inhibitors (ARIs) prevent peripheral
nerve dysfunction and morphological abnormalities in
animal models of diabetes. However, some experimen-
tal intervention studies and clinical trials of ARIs on
diabetic neuropathy (DN) appeared disappointing be-
cause of either 1) their inadequate design and, in
particular, insufficient correction of the sorbitol path-
way activity or 2) the inability to reverse established
functional and metabolic deficits of DN by AR inhibi-
tion in general. Moreover, it has recently been hypoth-
esized that the key physiological role of AR is the
detoxification of lipid peroxidation products, and thus
inhibition of the enzyme under diabetic conditions
could actually be detrimental rather than beneficial.
The present study was therefore designed 1) to evaluate
whether diabetes-induced neurovascular dysfunction,
nerve conduction deficits, and the key metabolic ab-
normalities can be reversed by treatment with an ade-
quate dose of ARI, i.e., a dose that completely inhibits
the increased sorbitol pathway activity, and thus to
assess the rationale for continued development of ARIs
for treatment of DN; and 2) to identify the relation
between AR and oxidative stress in the diabetic nerve by
evaluating an ARI on parameters of lipid peroxidation
and antioxidative defense.
PRINCIPAL FINDINGS
1. Treatment with an adequate dose of ARI reverses
diabetes-induced neurovascular dysfunction and nerve
conduction deficits
The experiments were performed in control rats and
streptozotocin-diabetic rats treated with or without
the ARI sorbinil at 65 mg kg1d1, the dose that
completely corrected diabetes-induced increase in
the sciatic nerve sorbitol pathway activity, for 2 wk
after 4 wk of untreated diabetes. ARI treatment
partially corrected diabetes-induced decrease in sci-
atic endoneurial nutritive blood flow (Fig. 1A) as-
sessed by microelectrode polarography and hydro-
gen clearance, did not affect mean systemic blood
pressure (Fig. 1B), and essentially corrected de-
creased endoneurial vascular conductance (Fig. 1C)
and motor (Fig. 1D) and sensory (Fig. 1E) nerve
conduction deficits.
2. Treatment with an adequate dose of ARI reverses
diabetes-induced key metabolic abnormalities such as
mitochondrial and cytosolic NAD/NADH redox
imbalances and energy deficiency in peripheral nerve
Free mitochondrial NAD/NADH ratio, a metabolic
measure of tissue oxygenation and mitochondrial oxi-
dative capacity, was calculated from the steady-state
metabolite concentrations and the equilibrium con-
stant of the -hydroxybutyrate dehydrogenase system.
This ratio was decreased in the sciatic nerve of diabetic
rats compared with nondiabetic controls and was par-
tially corrected in the ARI-treated diabetic group (Fig.
2A). In a similar fashion, free cytosolic NAD/NADH
ratio calculated from the steady-state metabolite con-
centrations and the equilibrium constant of the lactate
dehydrogenase system was decreased in the sciatic
nerve of diabetic rats compared with nondiabetic con-
trols, and this decrease was partially corrected in the
ARI-treated diabetic group (Fig. 2B). Administration of
ARI to diabetic rats reversed clearly manifested energy
failure (decrease in phosphocreatine/creatine ratio) in
peripheral nerve (Fig. 2C).
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3. Treatment with an adequate dose of ARI
counteracts rather than exacerbates diabetes-induced
lipid peroxidation and antioxidant loss in peripheral
nerve
Increased nerve lipid peroxidation manifested by accu-
mulation of malondialdehyde plus 4-hydroxyalkenals
was revealed in diabetic rats compared with nondia-
betic controls, and this activation was completely ar-
rested by an ARI treatment (Fig. 2D). The concentra-
tions of two major nonenzymatic antioxidants, GSH
(Fig. 2E) and ascorbate (Fig. 2F) were reduced in the
peripheral nerve of diabetic rats compared with nondi-
abetic controls, and the deficiency in both antioxidants
was essentially reversed in the ARI-treated diabetic
group .
CONCLUSIONS
The role for AR is the pathogenesis of peripheral DN is
supported by at least five lines of evidence: 1) similarity
of a number of functional, metabolic, and morpholog-
ical abnormalities in animal models of diabetes and
galactose feeding; 2) demonstration of preventive ef-
fects of structurally diverse ARIs on functional, bio-
chemical, and structural changes of DN; 3) potentiation
of galactose-induced neuropathy in the transgenic mice
expressing human AR and the absence of functional
deficits of DN in the AR knockout (AR/)mice; 4)
identification of high AR protein level as an indepen-
dent risk factor for DN in patients with type 1 (insulin-
dependent) and type 2 (non-insulin-dependent) diabe-
tes mellitus; and 5) the finding of a 30.2% increase in
the frequency of the Z-2 allele of the AR gene, known to
be associated with two- to threefold AR expression, in
patients with DN compared with uncomplicated group.
Despite such strong support of the AR concept of DN
from experimental and human studies, the contradic-
tory results of intervention animal studies and the
inefficacy of ARIs in clinical trials raised the question of
reversibility of existing abnormalities of peripheral DN
with AR inhibition. To address this question, we per-
formed experiments with the well-studied ARI sorbinil
administered at a dose known to entirely inhibit diabe-
tes-induced increase in the sorbitol pathway activity for
2 wk after 4 wk of untreated diabetes. We have previ-
ously demonstrated that the rat model with 3 wk of
streptozotocin diabetes displays clearly manifested pe-
ripheral nerve blood flow and conduction deficits,
NAD/NADH redox imbalances, energy deficiency,
and evidence of enhanced oxidative stress.
The present study clearly indicates that treatment
with adequate doses of ARIs, i.e., doses that completely
inhibit increased sorbitol pathway activity, is the most
effective approach for reversal of at least early diabetic
neuropathy, and that all major functional (nerve blood
flow and conduction deficits) and metabolic (mito-
chondrial and cytosolic NAD/NADH redox imbal-
ances, energy failure) changes are reversed by an ARI
therapy.
In the last several years, the debate about a ‘primary
mechanism’ of diabetic complications has centered on
oxidative stress and its relationship with other hyper-
glycemia-initiated factors. It has recently been sug-
gested that three pathways leading to diabetic com-
plications—increased sorbitol pathway activity,
nonenzymatic glycation/glycoxidation, and PKC activa-
tion—originate from oxidative stress, particularly pro-
duction of superoxide anion radicals in mitochondria.
This concept, at least the part related to the sorbitol
pathway, is not supported by experimental studies
Figure 1. Evaluation of an ARI on diabetes-induced changes
in peripheral nerve function. A) Sciatic endoneurial NBF. B)
Blood pressure (BP). C) Endoneurial vascular conductance
(VC). D) MNCV. E) SNCV (meanse, n10–12). C, controls;
D, untreated diabetic group; DARI, diabetic group treated
with ARI. *, **Significantly different vs. controls (P0.05 and
0.01, respectively); ##significantly different vs. untreated
diabetic group (P0.01).
Figure 2. Evaluation of an ARI on diabetes-induced changes
in the key metabolic variables and enhanced oxidative stress
in peripheral nerve. A) Free mitochondrial NAD/NADH
ratios; B) free cytosolic NAD/NADH ratios; C) PCr/Cr
ratios; D) lipid peroxidation product concentrations; E) GSH
concentrations; F) ascorbate concentrations (meanse,
n6–10). C, controls; D, untreated diabetic group; DARI,
diabetic group treated with ARI. **Significantly different vs.
controls (P0.01); #, ##significantly different vs. untreated
diabetic group (P0.05 and 0.01, respectively).
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demonstrating the absence of any suppression of tissue
sorbitol pathway activity by antioxidants, i.e., those
neutralizing superoxide anion radicals (dl--lipoic
acid, taurine, and probucol) in diabetic animal models.
Recently, several groups have put forward the hypoth-
esis that the key physiological role of AR is the detoxi-
fication of lipid peroxidation products and thus AR
inhibition in the diabetic conditions is detrimental
rather than beneficial. However, numerous experimen-
tal studies with administration of ARIs to control ani-
mals did not reveal an appearance of oxidative stress or
diabetes-like complications as observed with pro-oxi-
dants. The effects of ARIs and antioxidants on diabetic
complications (neuropathy) are unidirectional, i.e.,
both classes of agents prevent or delay diabetes-associ-
ated aberrations in nerve function, metabolism, neuro-
trophic support, and morphology. The present study
clearly demonstrates that treatment with adequate
doses of ARIs counteracts the most important manifes-
tations of oxidative injury, and that in relation to
oxidative stress, AR inhibition is beneficial rather than
harmful.
In conclusion, diabetes-induced neurovascular dys-
function, nerve conduction deficits, key metabolic
changes, and oxidative injury in early DN are reversed
by treatment with an adequate dose of ARI, i.e., the
dose that completely inhibits the increased sorbitol
pathway activity. Our findings support the key primary
role for AR in the pathogenesis of DN (Fig. 3) and thus
the need for continued development of new potent and
well-tolerated ARIs. Analysis of past ARI clinical trials
indicates their failure resulted from either inadequate
doses and insufficient inhibition of the sorbitol pathway
activity or unacceptably high systemic toxicity of the
inhibitors rather than inapplicability of the AR concept
for DN in humans. Robust inhibition of AR with
Zenarestat in diabetic human nerve has yielded dose-
dependent efficacy on nerve structure and function;
80% lowering of nerve sorbitol concentration appeared
to be required for improvement in nerve electrophysi-
ology and fiber density. Whereas experimental studies
in animal models indicate the reversibility of early DN,
clinical trials in the U.S. have been performed in
patients with nerve structural changes, i.e., far more
advanced DN, a stage of the disease that may be highly
resistant to any drug therapy. An approach more likely
to meet with success may be a prevention or early
intervention modeled on the experiments reported
here. The ARIs are widely used for treatment of pa-
tients with DN in Japan and are prescribed to patients
with newly diagnosed diabetes mellitus, together with
insulin or hypoglycemic agents, or with early small fiber
neuropathy. This approach is justified considering that
tight blood glucose control with the complete lack of
intermittent hyperglycemia is difficult, often impossi-
ble, to achieve and has not been shown to reverse
established neuropathy.
Figure 3. The key primary role for AR in functional, signal
transduction, metabolic, neurotrophic, and morphological
abnormalities characteristic for peripheral diabetic neuropa-
thy.
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